Prognostic value of copeptin in patients with aneurysmal subarachnoid hemorrhage.

Recently, copeptin has been identified as a serum prognosis marker in acute ischemic stroke and intracerebral hemorrhage (ICH). This study investigated the prognostic value of copeptin in the 243 patients with aneurysmal subarachnoid hemorrhage(aSAH). Upon admission, plasma copeptin levels were measured by enzyme-linked immunosorbent assay. The end points were mortality and poor functional outcome (Glasgow Outcome Scale score of 1–3) after 3 months. Median copeptin serum levels were 21.0 pmol/l (IQR 13.2–31.2). Patients with a poor outcome and nonsurvivors had significantly increased copeptin levels on admission (P < .001 both). In the multivariate analysis, for each 1 pmol/l increase of serum concentration of copeptin, the adjusted risk of poor outcomes and mortality would be increased by and 6% (1.06 [1.02–1.10], P < .001) and 9% (1.09 [1.03–1.13], P < .001), respectively. Receiver operating characteristics to predict functional outcome and mortality demonstrated areas under the curve of copeptin of 0.74 (95% confidence interval [CI], 0.67–0.81) and 0.81 (95% CI, 0.74–0.87), which was comparable with the WFNS score(P > .05) but superior to C-reactive protein and IL-6 (P < .01).Unlabelled Image